ArticleAnnals of the rheumatic diseases2022

Response to: 'Correspondence on 'Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial'' by Satis

Seza Ozen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.